J&J's Spra­va­to pulls a PhI­II win against Sero­quel XR in treat­ment-re­sis­tant de­pres­sion

A day be­fore Thanks­giv­ing, J&J’s Janssen has a new cut of Phase III Spra­va­to da­ta to be grate­ful for.

The phar­ma gi­ant an­nounced on Wednes­day that its nasal spray, al­so known as es­ke­t­a­mine, beat ex­tend­ed-re­lease que­ti­ap­ine, pre­vi­ous­ly sold by As­traZeneca as Sero­quel XR, in treat­ment-re­sis­tant de­pres­sion (TRD). Of 676 adults, a sig­nif­i­cant­ly high­er num­ber of pa­tients on Spra­va­to were able to achieve re­mis­sion and avoid re­lapse af­ter 32 weeks, ac­cord­ing to J&J.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.